Welcome guest, Sign in

Home

Michael Peter Smith

Michael Peter Smith

Education

Ph.D. in Molecular Cancer Studies, University of Manchester, 2013

Current position

CRUK Research Associate, University of Manchester, Claudia Wellbrock Lab (2014-present)

Publications

  1. Erice, O.*, Smith, M. P.*, White, R., Goicoechea, I., Barriuso, J., Jones, C., Margison, G. P., Acosta, J. C., Wellbrock, C. and Arozarena, I. (2015). MGMT expression predicts PARP-mediated resistance to temozolomide. Mol Cancer Ther 14(5): 1236-1246. (*Equal contribution)
  2. Smith, M. P., Sanchez-Laorden, B., O'Brien, K., Brunton, H., Ferguson, J., Young, H., Dhomen, N., Flaherty, K. T., Frederick, D. T., Cooper, Z. A., Wargo, J. A., Marais, R. and Wellbrock, C. (2014). The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov 4(10): 1214-1229.
  3. Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. and Wellbrock, C. (2013). Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst 105(1): 33-46.
Protocols by Michael Peter Smith
  1. Differentiation of THP1 Cells into Macrophages for Transwell Co-culture Assay with Melanoma Cells